<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>건강과 대안 &#187; 국내사망자 170명</title>
	<atom:link href="http://www.chsc.or.kr/tag/%EA%B5%AD%EB%82%B4%EC%82%AC%EB%A7%9D%EC%9E%90%20170%EB%AA%85/feed" rel="self" type="application/rss+xml" />
	<link>http://www.chsc.or.kr</link>
	<description>연구공동체</description>
	<lastBuildDate>Mon, 13 Apr 2026 01:34:28 +0000</lastBuildDate>
	<language>ko-KR</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.2</generator>
		<item>
		<title>[돼지독감] 신종플루 국내사망자 170명, 22명 추가 (12/17 기준)</title>
		<link>http://www.chsc.or.kr/?post_type=reference&#038;p=1598</link>
		<comments>http://www.chsc.or.kr/?post_type=reference&#038;p=1598#comments</comments>
		<pubDate>Tue, 29 Dec 2009 11:35:13 +0000</pubDate>
		<dc:creator>건강과대안</dc:creator>
				<category><![CDATA[식품 · 의약품]]></category>
		<category><![CDATA[국내사망자 170명]]></category>
		<category><![CDATA[돼지독감]]></category>
		<category><![CDATA[신종플루]]></category>
		<category><![CDATA[인플루엔자 유사환자 분율(ILI)]]></category>
		<category><![CDATA[질병관리본부]]></category>
		<category><![CDATA[항바이러스제 내성]]></category>

		<guid isPermaLink="false">http://www.chsc.or.kr/?post_type=reference&#038;p=1598</guid>
		<description><![CDATA[[질병관리본부 보도자료](2009.12.24)□&#160;인플루엔자&#160;유사환자&#160;분율(ILI)&#160;&#160;○&#160;2009년&#160;51주차&#160;ILI는&#160;12.32로&#160;50주&#160;대비&#160;33.8%&#160;감소&#160;&#160;&#160;※&#160;ILI(Influenza-Like&#160;Illness)&#160;:&#160;표본감시의료기관(12.1일&#160;현재&#160;전국&#160;814개소)&#160;외래&#160;환자&#160;1,000명당&#160;인플루엔자&#160;유사&#160;증상자수,&#160;‘09～’10절기&#160;유행&#160;주의보&#160;기준&#160;:&#160;2.6□&#160;실험실&#160;감시&#160;결과&#160;&#160;○&#160;항바이러스제&#160;내성&#160;검출&#160;:&#160;현재까지&#160;4건(785건&#160;대상)&#160;&#160;-&#160;4번째&#160;내성&#160;검출&#160;관련&#160;&#160;&#160;？&#160;2세(남아),&#160;11.26&#160;최초내원,&#160;12.8&#160;음성퇴원&#160;&#160;&#160;？&#160;타미플루&#160;2배&#160;증량과&#160;아만타딘&#160;병용치료로&#160;완치되었으며&#160;가족&#160;및&#160;의료진&#160;등에서&#160;추가감염&#160;없었음&#160;&#160;&#160;*&#160;타미플루&#160;내성지표인&#160;NA&#160;유전자의&#160;275번째&#160;아미노산이&#160;히스티딘(Histidine)에서&#160;티로신(Tyrosine)으로&#160;변이&#160;&#160;&#160;※&#160;전세계적으로&#160;총&#160;168건의&#160;타미플루&#160;내성주&#160;발견(WHO,&#160;12.23)&#160;□&#160;50주&#160;신종플루&#160;바이러스&#160;검출&#160;현황&#160;○&#160;전체&#160;검체건수&#160;중에&#160;신종플루&#160;바이러스가&#160;검출된&#160;비율은&#160;34.5%&#160;&#160;&#160;&#160;(160건/464건)임&#160;&#160;-&#160;49주&#160;52.1%&#160;←48주&#160;56.4%&#160;←&#160;47주&#160;50.8%&#160;←&#160;46주&#160;46.3%&#160;←&#160;45주&#160;51.2%&#160;□&#160;신종플루&#160;환자&#160;중&#160;합병증&#160;입원&#160;사례&#160;현황(12.19&#160;기준)&#160;○&#160;총&#160;50명이&#160;중증&#160;합병증으로&#160;중환자실&#160;입원&#160;중&#160;○&#160;신종플루&#160;관련&#160;사망사례는&#160;22건&#160;추가&#160;:&#160;총&#160;170건□&#160;항바이러스제&#160;투약현황○&#160;일일&#160;평균처방건수가&#160;전주대비&#160;25.4%&#160;감소]]></description>
				<content:encoded><![CDATA[<p>[질병관리본부 보도자료](2009.12.24)<BR><BR>□&nbsp;인플루엔자&nbsp;유사환자&nbsp;분율(ILI)&nbsp;<BR>&nbsp;○&nbsp;2009년&nbsp;51주차&nbsp;ILI는&nbsp;12.32로&nbsp;50주&nbsp;대비&nbsp;33.8%&nbsp;감소<BR>&nbsp;&nbsp;&nbsp;※&nbsp;ILI(Influenza-Like&nbsp;Illness)&nbsp;:&nbsp;표본감시의료기관(12.1일&nbsp;현재&nbsp;전국&nbsp;814개소)&nbsp;외래&nbsp;환자&nbsp;1,000명당&nbsp;인플루엔자&nbsp;유사&nbsp;증상자수,&nbsp;‘09～’10절기&nbsp;유행&nbsp;주의보&nbsp;기준&nbsp;:&nbsp;2.6<BR><BR>□&nbsp;실험실&nbsp;감시&nbsp;결과&nbsp;<BR>&nbsp;○&nbsp;항바이러스제&nbsp;내성&nbsp;검출&nbsp;:&nbsp;현재까지&nbsp;4건(785건&nbsp;대상)<BR>&nbsp;&nbsp;-&nbsp;4번째&nbsp;내성&nbsp;검출&nbsp;관련<BR>&nbsp;&nbsp;&nbsp;？&nbsp;2세(남아),&nbsp;11.26&nbsp;최초내원,&nbsp;12.8&nbsp;음성퇴원<BR>&nbsp;&nbsp;&nbsp;？&nbsp;타미플루&nbsp;2배&nbsp;증량과&nbsp;아만타딘&nbsp;병용치료로&nbsp;완치되었으며&nbsp;가족&nbsp;및&nbsp;의료진&nbsp;등에서&nbsp;추가감염&nbsp;없었음<BR>&nbsp;&nbsp;&nbsp;*&nbsp;타미플루&nbsp;내성지표인&nbsp;NA&nbsp;유전자의&nbsp;275번째&nbsp;아미노산이&nbsp;히스티딘(Histidine)에서&nbsp;티로신(Tyrosine)으로&nbsp;변이<BR>&nbsp;&nbsp;&nbsp;※&nbsp;전세계적으로&nbsp;총&nbsp;168건의&nbsp;타미플루&nbsp;내성주&nbsp;발견(WHO,&nbsp;12.23)&nbsp;<BR><BR>□&nbsp;50주&nbsp;신종플루&nbsp;바이러스&nbsp;검출&nbsp;현황<BR>&nbsp;○&nbsp;전체&nbsp;검체건수&nbsp;중에&nbsp;신종플루&nbsp;바이러스가&nbsp;검출된&nbsp;비율은&nbsp;34.5%<BR>&nbsp;&nbsp;&nbsp;&nbsp;(160건/464건)임<BR>&nbsp;&nbsp;-&nbsp;49주&nbsp;52.1%&nbsp;←48주&nbsp;56.4%&nbsp;←&nbsp;47주&nbsp;50.8%&nbsp;←&nbsp;46주&nbsp;46.3%&nbsp;←&nbsp;45주&nbsp;51.2%&nbsp;<BR><BR>□&nbsp;신종플루&nbsp;환자&nbsp;중&nbsp;합병증&nbsp;입원&nbsp;사례&nbsp;현황(12.19&nbsp;기준)<BR>&nbsp;○&nbsp;총&nbsp;50명이&nbsp;중증&nbsp;합병증으로&nbsp;중환자실&nbsp;입원&nbsp;중<BR>&nbsp;○&nbsp;신종플루&nbsp;관련&nbsp;사망사례는&nbsp;22건&nbsp;추가&nbsp;:&nbsp;총&nbsp;170건<BR><BR>□&nbsp;항바이러스제&nbsp;투약현황<BR><BR>○&nbsp;일일&nbsp;평균처방건수가&nbsp;전주대비&nbsp;25.4%&nbsp;감소</p>
]]></content:encoded>
			<wfw:commentRss>http://www.chsc.or.kr/?post_type=reference&#038;p=1598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
